Chemoimmunotherapy improves objective response rate and survival in advanced pulmonary large-cell neuroendocrine carcinomaCombining Chemotherapy and Immune Therapy Improves Outcomes for Advanced Lung Cancer

This meta-analysis evaluated the efficacy and safety of chemoimmunotherapy (combination of chemotherapy and immune checkpoint inhibitors) compared to chemotherapy alone in patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC). The analysis included a total sample size of 3537 patients. Because LCNEC is a relatively rare malignancy, this meta-analysis serves as a critical synthesis of available data to determine the impact of adding immune checkpoint inhibitors (ICI) to standard chemotherapy regimens.

The primary outcome measured was the objective response rate (ORR). The analysis reported an ORR of 49% for patients receiving chemoimmunotherapy (95% CI: 43-55). When comparing chemoimmunotherapy directly to chemotherapy alone, the study found a significantly improved ORR with an odds ratio (OR) of 2.52 (95% CI: 1.59-4.02). These results indicate a substantial clinical advantage in tumor shrinkage and response for patients receiving the combination therapy.

Secondary outcomes included progression-free survival (PFS) and overall survival (OS). For PFS, the study reported a median of 7.4 months with a hazard ratio (HR) of 0.51 (95% CI: 0.39-0.67). In the first-line setting, patients receiving chemoimmunotherapy showed improved OS with a hazard ratio (HR) of 0.72 (95% CI: 0.58-0.89). These figures suggest that the addition of ICIs to chemotherapy may significantly delay disease progression and extend life for patients with advanced LCNEC.

Safety and tolerability were also assessed by comparing grade 3 or higher adverse events between the two treatment groups. The analysis found no significant difference in these severe adverse events between chemoimmunotherapy and chemotherapy alone, reporting an odds ratio (OR) of 1.02 (95% CI: 0.64-1.64). This suggests that the addition of ICIs does not appear to increase high-grade toxicity compared to standard chemotherapy in this specific patient population.

These findings contribute to the broader understanding of LCNEC management, a condition where treatment options can be limited. While these results are promising, the study noted substantial heterogeneity across the included studies as a primary methodological limitation. Furthermore, because the underlying data were derived from observational or non-randomized sources, the association between chemoimmunotherapy and improved outcomes is established through meta-analysis rather than randomized controlled trials. Clinically, these results suggest that chemoimmunotherapy may be a preferred strategy for patients with advanced LCNEC to improve both response rates and survival without increasing the risk of severe toxicity. However, due to the substantial heterogeneity and the lack of prospective trial data in the current evidence base, clinicians should interpret these findings as indicative but not definitive. The results require confirmation through prospective trials to establish a standardized protocol for this patient population.

Several questions remain unanswered regarding the optimal sequencing of therapies, the specific ICI agents that provide the most significant benefit, and how different biomarkers might influence response rates in LCNEC patients. Further research is needed to address these gaps and refine treatment selection for this rare lung cancer.